BrightOwl Loader Loading


I am a scientist with a track record of finding practical solutions within Exploratory and Translational Medicine sciences. A dynamic and independent thinker supporting clinical trials and translating preclinical science into clinical practice. I have extensive management and leadership experience in a dynamic and innovative environment to support drug development of seven Biologics. CORE SKILLS AND ACHIEVEMENTS - Expertise in translational pharmacology and bio-analytical studies (biomarkers) within pre-clinical and clinical settings. Implementation of key cutting-edge bioassays supporting several clinical trials (Phase I-II and orphan drug indication) for inflammatory diseases and immune-related disorders. - Excellent organizational and prioritizing skills cultivated through project management of multiple concurrent drug development programs, including planning and monitoring of timelines, setting of budgets, and management of suppliers and CROs - Industrial experience with GLP, ICH, GCP, with regulatory experience participating in FDA and EMEA submissions. - Scientific writing including writing of preclinical/clinical reports, Investigator Brochures and regulatory documents.


Current Experience

  • Head of Translational Pharmacology Lab
    Since May 2009
    Identification of biomarkers, development of bioassays to characterise and validate monoclonal antibodies. Toxicology, preclinical and clinical studies. Generation of data for clinical pharmacology (models) Manager of the Gene expression platform Implementation of a ISO 17025 standard (Clinical testing lab) Management of 3 people.

Past Experience

  • Postdoctoral Fellow in Exploratory Science and Translational Medicine Department,
    May 2007 --- April 2009
    - In vitro assays to characterize and determine the mode of action of therapeutic antibodies. - Set-up of cellular assays, ex vivo and in vitro models for lead candidate identification and characterization - Development of the lead candidates (Epitope mapping, antibody engineering, germlining) (e.g. anti-IL-6R mAb) - Implementation of a testing laboratory for clinical samples following GLP rules. - Establishment of a L2 lab as a strategic resource for clinical sample analysis and the development of appropriate cell-based bioassays or whole blood assays

  • Ingénieur d'étude
    February 2007 --- April 2007
    Analysis of the neuropoietin's signaling pathway. Biochemistry, cellular biology in order to complete my PhD work.

  • PhD student
    February 2003 --- January 2007
    Generation of a murine model of neurodegenerative disease (Multiple Sclerosis). Knock-Out and conditional Knock-In mice, and cytokine Inactivation (neutralizing mAbs and cytokine trap) Rôle des ligands du CNTFR dans le développement et étude de la signalisation induite pas ces cytokines dans des modèles cellulaires de cancer. Compétences acquises: Biologie cellulaire, biologie moléculaire (construction d'une souris Knock-In), Biochimie, Immunologie, neurobiologie. Teaching : « Innovations in biotechnology » Biochemistry, Master students, ISTIAA, Angers, France

  • Junior Engineer
    February 2002 --- January 2003
    Study of prion protein structure and chimeric protein. Conversion in scrapie form (Biochemistry and molecular biology) with work in a P3 lab


LinkedIn Assessment :
pharmacologyClinical DevelopmentClinical trialsBiomarkersMonoclonal AntibodiesPharmacodynamicsClinical researchmolecular biologyCell Based AssaysIn VitroBiotechnologyTherapeuticsCROImmunologyPhase ITranslational MedicineToxicologyNeuroscienceCancer


  • PhD in Pharmacology from Université de Montréal in 2007
  • Master's degree in Biology, protein engineering from Polytech'Clermont-Ferrand in 2002
  • Master's degree (DEA) in Physiologie et génétique moléculaires from Université Blaise Pascal (Clermont-II) - Clermont-Ferrand in 2002
  • DEUG in Sciences de la Vie from Université Blaise Pascal (Clermont-II) - Clermont-Ferrand in 1999

Area / Region

Beaumont, France


Driving License
  • No